AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

European stocks look like newly good investments amid Trump's tariff war and US economic unpredictabilities. European defense stocks are particularly appealing.

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...